“…Recently, CRISPR-Cas has emerged as a powerful technology that is revolutionizing next-generation diagnostic platforms [6] , [7] . The mechanism of CRISPR-Cas systems, which are programmed by CRISPR guide RNA (crRNA), has been reported to not only cleave the target nucleic acid but also cleave all neighbouring nucleic acids indiscriminately [8] , [9] . This target-triggered collateral activity of CRISPR-Cas systems has stimulated the development of CRISPR-based biosensing technologies [10] , [11] , which offer unique advantages of simple fabrication, ultrahigh sensitivity, high specificity to single-base variation, and good amenability for POC diagnostics [12] , [13] , [14] .…”